IceCure Medical (NASDAQ:ICCM) Stock Rating Reaffirmed by HC Wainwright

IceCure Medical (NASDAQ:ICCMGet Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 132.56% from the stock’s previous close.

Separately, Alliance Global Partners increased their price target on IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a report on Wednesday, March 20th.

Check Out Our Latest Research Report on IceCure Medical

IceCure Medical Stock Performance

NASDAQ ICCM opened at $1.29 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.66 and a quick ratio of 3.08. IceCure Medical has a 1-year low of $0.52 and a 1-year high of $1.57. The firm has a market capitalization of $58.85 million, a P/E ratio of -3.91 and a beta of 0.73. The business’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.11.

IceCure Medical (NASDAQ:ICCMGet Free Report) last posted its quarterly earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. IceCure Medical had a negative net margin of 453.76% and a negative return on equity of 86.96%. The firm had revenue of $1.26 million for the quarter. During the same quarter in the previous year, the business posted ($0.11) EPS. Equities analysts predict that IceCure Medical will post -0.28 EPS for the current year.

Hedge Funds Weigh In On IceCure Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in shares of IceCure Medical during the second quarter worth $78,000. UBS Group AG lifted its holdings in IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after buying an additional 26,919 shares in the last quarter. Boothbay Fund Management LLC boosted its position in IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after buying an additional 20,000 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of IceCure Medical by 57.2% during the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after acquiring an additional 20,159 shares in the last quarter. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

See Also

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with's FREE daily email newsletter.